Table 1 Table showing baseline data and final data for all outcome measures
GTN 0.03 mg/24 h (n = 41)GTN 0.06 mg/24 h (n = 34)GTN 0.15 mg/24 h (n = 44)Placebo (n = 35)
Pain with activity38 (−4) (SD 3.17)30 (−2.8) (SD 2.38)36 (−3.9) (SD 2.11)32 (−3.8) (SD 2.62)
Patient at rest38 (−3) (SD 2.45)30 (−1.7) (SD 2.25)36 (−1.8) (SD 2.23)32 (−2.6) (SD 1.98)
Pain at night34 (−3.2) (SD 2.83)28 (−2.6) (SD 2.2)32 (−2.1) (SD 1.86)30 (−2.3) (SD 1.9)
Painfree grip strength (kg)20.8 (8.2) (SD 9.82)24.3 (8.8) (SD 12.77)23.1 (7.4) (SD 12.15)22.9 (4.5) (SD 8.48)
Maximum force ORI-TETS (kg)0.5 (0.4) (SD 0.71)0.7 (0.3) (SD 0.51)0.7 (0.4) (SD 0.72)0.5 (0.2) (SD 0.4)
Subjective global assessment of change38 (−3.5) (SD 3.05)30 (−2.4) (SD 2.59)36 (−3.2) (SD 2.38)32 (−3.1) (SD 2.66)
  • GTN, glyceryl trinitrate; ORI-TETS, Orthopaedic Research Institute-Tennis Elbow Testing System.

  • Baseline data is presented above, with change from baseline in brackets below, and standard deviations in parentheses.